Senseonics (NYSE:SENS) Coverage Initiated by Analysts at StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of Senseonics (NYSE:SENSGet Free Report) in a research note issued to investors on Tuesday. The firm set a “sell” rating on the stock.

Senseonics Price Performance

Shares of SENS stock opened at $0.37 on Tuesday. The company has a debt-to-equity ratio of 1.79, a current ratio of 3.96 and a quick ratio of 3.70. The company has a market capitalization of $194.41 million, a PE ratio of -2.62 and a beta of 0.82. The firm’s 50-day moving average is $0.44 and its two-hundred day moving average is $0.53. Senseonics has a 12 month low of $0.37 and a 12 month high of $1.05.

Senseonics (NYSE:SENSGet Free Report) last released its quarterly earnings results on Monday, May 13th. The company reported ($0.03) EPS for the quarter, meeting the consensus estimate of ($0.03). Senseonics had a negative net margin of 346.38% and a negative return on equity of 202.32%. The firm had revenue of $5.05 million for the quarter, compared to analyst estimates of $4.76 million. Analysts predict that Senseonics will post -0.13 earnings per share for the current year.

Hedge Funds Weigh In On Senseonics

Hedge funds have recently modified their holdings of the business. RPO LLC purchased a new position in shares of Senseonics during the 4th quarter worth approximately $37,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in Senseonics by 30.2% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 909,931 shares of the company’s stock worth $483,000 after purchasing an additional 211,128 shares in the last quarter. State Board of Administration of Florida Retirement System purchased a new position in shares of Senseonics during the first quarter worth $91,000. Vanguard Group Inc. grew its stake in shares of Senseonics by 0.7% in the first quarter. Vanguard Group Inc. now owns 22,525,039 shares of the company’s stock valued at $11,963,000 after buying an additional 155,715 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its stake in shares of Senseonics by 16.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 367,200 shares of the company’s stock valued at $196,000 after buying an additional 51,000 shares in the last quarter. 12.36% of the stock is currently owned by hedge funds and other institutional investors.

Senseonics Company Profile

(Get Free Report)

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.

Further Reading

Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.